Given the degree of reported impairment based on PedsQL™ scores across different pediatric chronic conditions, the need for more efficacious targeted treatments for those pediatric patients with more severely impaired HRQOL is clearly and urgently indicated.
Given the limitation of using mouse systems to develop human therapeutics, the use of these approaches can provide more physiologically relevant insight into disease pathology and help to identify more efficacious drug targets.
Since CCL heterodimers of related chemokines have been described, the proposed small molecule therapeutic approach targeting the inhibition of QC/isoQC might be more efficacious than targeting a single CCL by passive immunization or a CCR by a specific receptor antagonist, proposed recently as a 'multiple receptor approach' by Koenen and Weber (Koenen & Weber, 2010).
In case of explicit redundancy within the IL-10 cytokine family, modulation of their expression could prove more efficacious than targeting the cytokines individually.
Thus, NAD(P H generation may be a more efficacious therapeutic target upstream of GSH and ROS.
Animal models of GBM are essential for the evaluation of more efficacious molecularly targeted therapies, in particular whether they can faithfully replicate both the relevant signaling pathway alterations and the histopathological hallmarks of human GBM.
There is, therefore, a need for new and more efficacious agents, targeted not only at treatment, but also at prevention of the disease, its progression, and its associated complications.
A number of currently available anti-thrombotic drugs (e.g. aspirin and clopidogrel) are hampered by associated side effects including severe bleeding (Barrett et al., 2008; Mackman, 2008; Michelson, 2008), and therefore, the development of safer, more efficacious and target-specific drugs to prevent thrombosis is a pressing priority.
RGD-PEG liposomes, targeted to angiogenic endothelial cells, proved to be no more efficacious than passively targeted PEG liposomes, indicating that active targeting and cell-specific delivery of VDAs do not offer an advantage over target tissue delivery in this tumour model.
